Thermo Fisher Scientific TMO has witnessed a significant interest from investors and asset management firms globally. The company's
shares have been acquired by several firms including
Livforsakringsbolaget Skandia,
Cwm LLC,
Artemis Investment Management,
New England Research & Management Inc,
Atomi Financial Group Inc,
Tealwood Asset Management, and
CCLA Investment Management. Despite a seeming setback when news broke of a
breach of FDA rules at a plant making infant RSV drugs, the company has consistently
outperformed the market. Over the last five years, TMO's stock has shown an impressive
growth of 113%. With increased
Short Interest, the company has made efforts to expand its
biopharma services and focus on sustainable packaging for
Invitrogen antibodies. TMO has also been noted for its attractive financial prospects, improved relative price performance, and rising strength. The company's continuous innovation in next-generation sequencing technology is positioned to advance
myeloid cancer clinical research. Meanwhile, billionaries show bullish behaviour on the stock, and successful earnings reports and speculation of a good third quarter for 2024 have kept expectations high.
Thermo Fisher Scientific TMO News Analytics from Wed, 06 Mar 2024 08:00:00 GMT to Sat, 12 Oct 2024 11:31:34 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -4
